Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Doptelet | avatrombopag | severe thrombocytopenia associated with chronic liver disease (CLD) | Pending | |||
Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Pending | |||
Ryaltris | olopatadine hydrochloride and mometasone | Seasonal allergic rhinitis | Pending | |||
TBC | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Pending | |||
TBC | momelotinib | Myelofibrosis | Pending | |||
Oncaspar | pegaspargase | Adult Acute Lymphocytic Leukemia (ALL) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Zevalin | iIbritumomab tiuxetan | Non-Hodgkin’s Lymphoma (NHL) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Demylocan | decitabine | Myelodysplastic Syndromes | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Viibryd | vilazodone | Depression, Major depressive disorder | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Imbruvica | ibrutinib | Leukemia | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |